Novartis AG (NVS) |
| 150.62 0.24 (0.16%) 10-16 16:00 |
| Open: | 150.785 |
| High: | 151.745 |
| Low: | 150.105 |
| Volume: | 1,728,793 |
| Market Cap: | 286,286(M) |
| PE Ratio: | 17.33 |
| Exchange: | New York Stock Exchange |
| Industry: | Drug Manufacturers - General |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 177.34 |
| Resistance 1: | 151.83 |
| Pivot price: | 144.21 |
| Support 1: | 142.89 |
| Support 2: | 137.37 |
| 52w High: | 170.46 |
| 52w Low: | 121.57 |
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Financials
| EPS | 6.620 |
| Book Value | 21.860 |
| PEG Ratio | 3.35 |
| Gross Profit | 22.374 |
| Profit Margin (%) | 22.50 |
| Operating Margin (%) | 34.62 |
| Return on Assets (ttm) | 10.3 |
| Return on Equity (ttm) | 30.4 |
Company news
Fri, 16 Oct 2026
Novartis (NVS) Halts Fabhalta Lupus Nephritis Trial Amid Strategic Shift - GuruFocus
Fri, 16 Oct 2026
Novartis AG (NVS) Stock Forecasts - Yahoo! Finance Canada
Fri, 16 Oct 2026
Novartis (NVS) Halts Fabhalta Lupus Nephritis Trial Amid Strategic Shift - GuruFocus
Fri, 16 Oct 2026
Novartis halts mid-stage trial for kidney drug, Fabhalta, in lupus nephritis - Seeking Alpha
Thu, 15 Oct 2026
Novartis AG Stock (NVS) Moved Up by 3.00% on Oct 15: Drivers Behind the Movement - TradingKey
Thu, 15 Oct 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS - PR Newswire
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
